Clinical Trials
10 trialsNCT07617337 2026-06-01
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
Chugai Pharmaceutical
Phase 1 Not yet recruiting
NCT07556549 2026-05-22
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Pfizer
Active not recruiting
NCT05297890 2026-05-19
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals
Phase 2 Active not recruiting
NCT07567352 2026-05-12
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
Pfizer
Active not recruiting
NCT06282991 2026-03-10
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Pfizer
Completed
NCT06678555 2026-02-05
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Pfizer
Active not recruiting
NCT05144997 2025-12-17
Lorlatinib Continuation Study
Pfizer
Phase 4 Active not recruiting
NCT03052608 2025-11-25
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Pfizer
Phase 3 Active not recruiting
NCT03909971 2025-11-05
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Pfizer
Phase 2 Completed
NCT04362072 2025-06-11
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Pfizer
Phase 4 Completed